journal article·2026-02-20

Controlled Synthesis and Drug Encapsulation of Poly(lactic- co -glycolic acid) Nanoparticles Using a Continuous Flow-Focusing Microfluidic Platform

Muhammad Mubashar Saeed, Matteo Tollemeto, Lasse H. E. Thamdrup, Anja Boisen, Eadaoin Carthy, Nicholas Dunne, David Kinahan

ACS Applied Nano Materials· Volume 9· Issue 7
Publisher page

Abstract

Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are widely studied for drug delivery due to their biocompatibility, biodegradability, and tuneable release characteristics. However, conventional synthesis methods often suffer from limited scalability and poor control over physicochemical properties. In this study, a hydrodynamic flow focusing microfluidic platform was applied to synthesise PLGA NPs via nanoprecipitation, enabling precise modulation of formulation parameters. The effects of flow rate ratio (FRR), PLGA concentration, and poly(vinyl alcohol) (PVA) surfactant concentration on NP size, polydispersity index (PDI), and zeta potential were systematically evaluated. Mixing time calculations under varying FRR indicated that lower FRRs promoted faster interfacial mixing; resulting in smaller, more uniform particles. Increasing PLGA concentration produced larger NPs due to viscosity-driven diffusion limitations, while optimising PVA concentration improved mixing efficiency and particle stabilisation, minimising particle size and PDI. Both hydrophilic (rhodamine B) and hydrophobic (curcumin) compounds were successfully encapsulated, confirming the platform’s versatility. This microfluidic approach offers a scalable and reproducible approach for fabricating highquality PLGA NPs; thus supporting their application in targeted and controlled drug delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Pickering emulsions and particle stabilization · Innovative Microfluidic and Catalytic Techniques Innovation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

ML-Laboratories Centre for Research Training

Dublin City University

School of Mechanical and Manufacturing Engineering

Biodesign Europe

RAPID Institute

The Danish National Research Foundation and Villum Foundation’s Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Ørsteds Plads 345C, 2800 Kongens Lyngby, Denmark

Centre for Medical Engineering Research

Advanced Manufacturing Research Centre (I-Form)

School of Pharmacy

Queen’s University Belfast

Funding

Irish Research Council · Novo Nordisk Fonden

References (68)

Show source-provided references
1. 10.3389/fmicb.2023.115562210.3389/fmicb.2023.1155622 ↗
2. 10.3390/polym1422496110.3390/polym14224961 ↗
3. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
4. 10.3390/pharmaceutics1412272810.3390/pharmaceutics14122728 ↗
5. 10.1163/15685620677599732210.1163/156856206775997322 ↗
6. 10.1007/s40242-025-5042-810.1007/s40242-025-5042-8 ↗
7. 10.1016/j.ijpharm.2023.12258710.1016/j.ijpharm.2023.122587 ↗
8. 10.1186/s12885-020-06803-710.1186/s12885-020-06803-7 ↗
9. 10.1039/C7NR06898K10.1039/C7NR06898K ↗
10. 10.1186/s12951-021-00812-910.1186/s12951-021-00812-9 ↗
11. 10.3390/toxins1507046110.3390/toxins15070461 ↗
12. 10.1016/j.intimp.2024.11253810.1016/j.intimp.2024.112538 ↗
13. 10.1016/j.bioactmat.2022.05.03010.1016/j.bioactmat.2022.05.030 ↗
14. 10.1038/s41598-021-94175-810.1038/s41598-021-94175-8 ↗
15. 10.1002/adfm.20221232610.1002/adfm.202212326 ↗
16. 10.1016/j.micpath.2024.10708310.1016/j.micpath.2024.107083 ↗
17. 10.1016/j.ijpharm.2024.12456710.1016/j.ijpharm.2024.124567 ↗
18. 10.3390/pharmaceutics1306081610.3390/pharmaceutics13060816 ↗
19. 10.1021/acsomega.8b0276710.1021/acsomega.8b02767 ↗
20. 10.3390/ijms2305252210.3390/ijms23052522 ↗
21. 10.1007/s40005-019-00441-310.1007/s40005-019-00441-3 ↗
22. 10.1039/D5LC00194C10.1039/D5LC00194C ↗
23. 10.3390/pharmaceutics1709115010.3390/pharmaceutics17091150 ↗
24. 10.1038/s41598-020-63234-x10.1038/s41598-020-63234-x ↗
25. 10.1038/s41598-018-20754-x10.1038/s41598-018-20754-x ↗
26. 10.1016/j.actbio.2020.12.02410.1016/j.actbio.2020.12.024 ↗
27. 10.1039/C8RA08972H10.1039/C8RA08972H ↗
28. 10.1039/c002866e10.1039/c002866e ↗
29. 10.1038/s41598-017-05184-510.1038/s41598-017-05184-5 ↗
30. 10.1016/j.ijpharm.2024.12490510.1016/j.ijpharm.2024.124905 ↗
31. 10.1038/s41598-020-76477-510.1038/s41598-020-76477-5 ↗
32. 10.1016/j.ijpharm.2022.12236810.1016/j.ijpharm.2022.122368 ↗
33. 10.4103/1735-5362.26820710.4103/1735-5362.268207 ↗
34. 10.3389/fmolb.2021.67754710.3389/fmolb.2021.677547 ↗
35. 10.1016/j.cej.2024.14937710.1016/j.cej.2024.149377 ↗
36. 10.1063/5.008176910.1063/5.0081769 ↗
37. 10.1016/j.sna.2013.11.01010.1016/j.sna.2013.11.010 ↗
38. 10.1007/s10404-012-1007-610.1007/s10404-012-1007-6 ↗
39. 10.1039/c0lc00599a10.1039/c0lc00599a ↗
40. 10.7150/thno.9926010.7150/thno.99260 ↗
41. 10.1562/0031-8655(2000)0720625EOSOTE2.0.CO210.1562/0031-8655(2000)0720625EOSOTE2.0.CO2 ↗
42. 10.1007/s00216-011-5415-310.1007/s00216-011-5415-3 ↗
43. 10.1021/nl801736q10.1021/nl801736q ↗
44. 10.1088/0960-1317/16/5/02010.1088/0960-1317/16/5/020 ↗
45. 10.1016/0735-1933(94)90046-910.1016/0735-1933(94)90046-9 ↗
46. Bruus H. · 2007
47. 10.1016/j.bioadv.2023.21364910.1016/j.bioadv.2023.213649 ↗
48. 10.3762/bjnano.10.22010.3762/bjnano.10.220 ↗
49. 10.1038/nrd149410.1038/nrd1494 ↗
50. 10.1039/C5NR03543K10.1039/C5NR03543K ↗
51. 10.3390/pharmaceutics1111059010.3390/pharmaceutics11110590 ↗
52. 10.3390/ijms15122390910.3390/ijms151223909 ↗
53. 10.1007/s13204-018-0790-010.1007/s13204-018-0790-0 ↗
54. 10.1007/s13204-018-0790-010.1007/s13204-018-0790-0 ↗
55. 10.3390/molecules2818667910.3390/molecules28186679 ↗
56. 10.1016/j.ijpharm.2004.11.02710.1016/j.ijpharm.2004.11.027 ↗
57. 10.1016/j.ijpharm.2024.12493410.1016/j.ijpharm.2024.124934 ↗
58. 10.1016/S0168-3659(02)00127-X10.1016/S0168-3659(02)00127-X ↗
59. 10.1371/journal.pone.008732610.1371/journal.pone.0087326 ↗
60. 10.3389/fphar.2022.99050510.3389/fphar.2022.990505 ↗
61. 10.1615/CritRevTherDrugCarrierSyst.v21.i5.2010.1615/CritRevTherDrugCarrierSyst.v21.i5.20 ↗
62. 10.1021/acs.langmuir.7b0433510.1021/acs.langmuir.7b04335 ↗
63. 10.1016/j.jcis.2021.03.03510.1016/j.jcis.2021.03.035 ↗
64. 10.3389/fphar.2016.0045810.3389/fphar.2016.00458 ↗
65. 10.1021/acsnano.9b0392410.1021/acsnano.9b03924 ↗
66. 10.1155/2015/34184810.1155/2015/341848 ↗
67. 10.3390/polym1211275110.3390/polym12112751 ↗
68. 10.1248/bpb.b17-0103610.1248/bpb.b17-01036 ↗